Jefferson University Hospitals

Physician Profile

Sergio Jimenez, MD

Jefferson University Physician

Academic Title: Professor
Director, Scleroderma Center

Specialties
Rheumatology (Not Accepting New Patients)

Office Locations

Philadelphia
Bluemle Life Sciences Bldg.
233 S. 10th Street, Ste. 509
Philadelphia PA 19107
Phone: (215) 503-5785
Fax: (215) 923-4649

Medical Services

Years in Practice

44

Board Certifications

  • Internal Medicine

Hospital Affiliation / Admitting Privileges

  • Thomas Jefferson University Hospital

Awards and Honors

Fellow, Royal College of Physicians 2010

Charles Slocumb Award for Excellence in Rheumatology 2009

Master, American College of Rheumatology 2008

Notes

Dr. Jimenez's practice is limited to: Scleroderma, Systemic Sclerosis, Nephrogenic Systemic Fibrosis and Fibrosing Disorders

Education

  • San Marcos University, Peru, Medical School

Internship

  • Philadelphia General Hospital
  • Hospital of the University of Pennsylvania

Residency

  • Mayo Clinic, Rochester
  • Philadelphia General Hospital

Fellowship

  • Hospital of the University of Pennsylvania

Recent Publications

PTP4A1 promotes TGFβ signaling and fibrosis in systemic sclerosis

Update of EULAR recommendations for the treatment of systemic sclerosis

Endothelial cell-specific activation of transforming growth factor-β signaling in mice induces cutaneous, visceral, and microvascular fibrosis

Multiplex assessment of serum cytokine and chemokine levels in idiopathic morphea and vitamin K1-induced morphea

Review article: pathogenesis and clinical manifestations of gastrointestinal involvement in systemic sclerosis

Human fibrotic diseases: Current challenges in fibrosis research

Exosomes isolated from serum of systemic sclerosis patients display alterations in their content of profibrotic and antifibrotic microRNA and induce a profibrotic phenotype in cultured normal dermal fibroblasts

Stimulation of transforming growth factor-β1-induced endothelial-to-mesenchymal transition and tissue fibrosis by endothelin-1 (ET-1): A novel profibrotic effect of ET-1

Role of muscarinic-3 receptor antibody in systemic sclerosis: Correlation with disease duration and effects of IVIG

Endothelial to mesenchymal transition (EndoMT) in the pathogenesis of Systemic Sclerosis-associated pulmonary fibrosis and pulmonary arterial hypertension. Myth or reality?

Severe eosinophilic fasciitis: Comparison of treatment with d-penicillamine plus corticosteroids vs. corticosteroids alone

Treatment of rapidly progressive systemic sclerosis: Current and futures perspectives

Biomarkers in systemic sclerosis

Endothelial Cells Expressing Endothelial and Mesenchymal Cell Gene Products in Lung Tissue from Patients with Systemic Sclerosis-Associated Interstitial Lung Disease

Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: A 10-year longitudinal study from the EUSTAR database

Joint and tendon involvement predict disease progression in systemic sclerosis: A EUSTAR prospective study

A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: A EUSTAR prospective study

Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- And tissue-specific microRNAs

The significance of macrophage polarization subtypes for animal models of tissue fibrosis and human fibrotic diseases

Role of cellular senescence and NOX4-mediated oxidative stress in systemic sclerosis pathogenesis